{"id":"standard-intensity-warfarin","safety":{"commonSideEffects":[{"rate":"2–3% per year (major); higher with supratherapeutic INR","effect":"Bleeding (major and minor)"},{"rate":"0.01–0.1%","effect":"Warfarin-induced skin necrosis"},{"rate":"1–2%","effect":"Gastrointestinal bleeding"},{"rate":"0.5–1%","effect":"Intracranial hemorrhage"},{"rate":"common; requires INR monitoring","effect":"Drug interactions (food, medications)"}]},"_chembl":{"chemblId":"CHEMBL1464","moleculeType":"Small molecule","molecularWeight":"308.33"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Warfarin acts as a vitamin K antagonist, blocking the enzyme vitamin K epoxide reductase and preventing the carboxylation of clotting factors II, VII, IX, and X in the liver. This reduces the production of functional coagulation factors and prolongs the prothrombin time (PT/INR), thereby decreasing the risk of thromboembolism. Standard intensity warfarin dosing is titrated to maintain an INR of 2–3 for most indications.","oneSentence":"Warfarin inhibits vitamin K-dependent clotting factors (II, VII, IX, X) to reduce thrombus formation and prevent blood clots.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:38:02.327Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Atrial fibrillation for stroke prevention"},{"name":"Venous thromboembolism (DVT/PE) treatment and prevention"},{"name":"Mechanical heart valve thromboprophylaxis"},{"name":"Acute myocardial infarction with high thromboembolic risk"}]},"trialDetails":[{"nctId":"NCT05646394","phase":"","title":"Registry on Augmented Antithrombotic Treatment Regimens for Patients With Arterial Thrombotic APS","status":"RECRUITING","sponsor":"McMaster University","startDate":"2022-07-01","conditions":"Antiphospholipid Syndrome, Arterial Thrombosis","enrollment":150},{"nctId":"NCT07081035","phase":"PHASE4","title":"Trial of Low-intensity Anticoagulation to Reduce GI or Other Bleeding Complications With Equivalent Therapeutic Efficacy in HeartMate 3 LVAD Patients","status":"NOT_YET_RECRUITING","sponsor":"Asan Medical Center","startDate":"2025-10","conditions":"Advanced Heart Failure, Left Ventricular Assist Devices, Anticoagulation Treatment","enrollment":94},{"nctId":"NCT05122780","phase":"PHASE4","title":"Prognostic Value of Precision Medicine in Patients With MINOCA (PROMISE Trial).","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","startDate":"2021-07-01","conditions":"Myocardial Infarction With Non-Obstructive Coronary Arteries","enrollment":120},{"nctId":"NCT01996657","phase":"","title":"D-Dimer Determined Anticoagulation INTENSITY in Patients With Mechanical Valve Replacement","status":"COMPLETED","sponsor":"Wuhan Asia Heart Hospital","startDate":"2013-01","conditions":"Heart Valve Disease","enrollment":772},{"nctId":"NCT02646267","phase":"PHASE4","title":"The Efficacy and Safety Study of Dabigatran and Warfarin to Non-valvular Atrial Fibrillation Patients","status":"UNKNOWN","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2016-03","conditions":"Atrial Fibrillation","enrollment":210},{"nctId":"NCT01438580","phase":"PHASE4","title":"The Effect and Safety of Different Intensity Anticoagulation Therapy in Elderly Patients With Non-valvular Atrial Fibrillation","status":"COMPLETED","sponsor":"Nanjing Medical University","startDate":"2010-01","conditions":"Atrial Fibrillation","enrollment":260}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":13,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"standard intensity warfarin","genericName":"standard intensity warfarin","companyName":"The First Affiliated Hospital with Nanjing Medical University","companyId":"the-first-affiliated-hospital-with-nanjing-medical-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Warfarin is a small molecule used as a vitamin K antagonist in standard intensity. It is studied for various conditions, including Antiphospholipid Syndrome, Arterial Thrombosis, and Heart Valve Disease, often in combination with other antithrombotic therapies.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}